Effect of Combination Therapies with Methotrexate, Sulfasalazine and Hydroxychloroquine on Hyperlipemia of Rheumatoid Arthritis
- VernacularTitle:甲氨蝶呤、柳氮磺吡啶、硫酸羟氯喹联合治疗类风湿关节炎对血脂的影响
- Author:
Hongmei ZHENG
;
Ziyu DENG
- Publication Type:Journal Article
- Keywords:
Disease-modifying anti-rheumatic drugs;
Arthritis;
Rheumatoid;
Blood lipid
- From:
Journal of Kunming Medical University
2013;(8):63-66
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of combination therapies with methotrexate, sulfasalazine and hydroxychloroquine on hyperlipemia of rheumatoid arthritis.Method From 2009 November to 2010 November, 68 RA inpatients and outpatients in the department of rheumatism of our hospital were randomly divided into two groups: A group and B group, 34 cases in each group. The patients in A group were given combination of methotrexate, sulfasalazine, hydroxychloroquine sulfate for the treatment of RA,patients in B group, based on A group's treatment, were treated by xuezhikang. Some indexes were observed in two group before treatment and 6 months after treatment, including cholesterolTC,low density lipoprotein cholesterol LDL-C , triglyceride TG , high density lipoprotein cholesterol HDL-C , swelling index, joint pain index, time of morning stiffness, C-reactive protein CRP , erythrocyte sedimentation rate ESR and DAS28. Results After 6 months’ treatment, the serum levels of TC, TG,, LDL-C, both in two groups of patients, were lower than those before treatment, and HDL-C was higher than that before treatment, there were significant differences (P<0.05 or P<0.01) . After 6 months of treatment,DAS28,ESR,CRP,joint tenderness,joint swelling and morning stiffness time, both in two groups RA patients, significantly reduced compared with before treatment, there were a very significant difference (P<0.05 or P<0.01) .After treatment, the above indexes had no statistically significant difference between two groups (P>0.05) . Conclusion RA patients have abnormal blood lipid levels, disease-modifying anti-rheumatic drugs have effect on blood lipid during remission joint disease in RA patients.
